1
|
Karachaliou N, Codony-Servat J, Bracht JWP, Ito M, Filipska M, Pedraz C, Chaib I, Bertran-Alamillo J, Cardona AF, Molina MA, Rosell R. Characterising acquired resistance to erlotinib in non-small cell lung cancer patients. Expert Rev Respir Med 2019; 13:1019-1028. [PMID: 31411906 DOI: 10.1080/17476348.2019.1656068] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Introduction: The therapy of patients with lung adenocarcinoma has significantly changed after the discovery of epidermal growth factor receptor (EGFR) mutations. EGFR mutations occur in 10-15% of Caucasian lung cancer patients and are associated with favorable outcome to orally administered EGFR tyrosine kinase inhibitors (TKIs), like erlotinib. However, as soon as the tumor cells are under the pressure of the specific inhibitor, compensatory signaling pathways are activated and resistance emerges. Areas covered: In this review we will focus on the mechanisms of resistance to the first-generation EGFR TKI, erlotinib, and will mainly summarize the findings throughout the last 10 years in the field of EGFR-mutant lung cancer. Expert opinion: Widespread research has been performed and several mechanisms of resistance to EGFR TKIs, especially first- and second-generation, have been identified. Still, no adequate combinatory therapies have received regulatory approval for the treatment of EGFR-mutant patients at the time of resistance. The third-generation EGFR TKI, osimertinib has been approved for patients whose tumor has become resistant through the secondary T790M resistant EGFR mutation. The identification of the mechanisms of resistance and the application of the adequate therapy to each patient is still an unmet need.
Collapse
Affiliation(s)
- Niki Karachaliou
- Global Clinical Development, Merck Healthcare KGaA , Darmstadt , Germany
| | - Jordi Codony-Servat
- Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus University Institute , Barcelona , Spain
| | | | - Masaoki Ito
- Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus University Institute , Barcelona , Spain
| | - Martyna Filipska
- Cancer Biology and Precision Medicine, Institut d'Investigació en Ciències Germans Trias i Pujol , Badalona , Spain
| | - Carlos Pedraz
- Cancer Biology and Precision Medicine, Institut d'Investigació en Ciències Germans Trias i Pujol , Badalona , Spain
| | - Imane Chaib
- Cancer Biology and Precision Medicine, Institut d'Investigació en Ciències Germans Trias i Pujol , Badalona , Spain
| | - Jordi Bertran-Alamillo
- Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus University Institute , Barcelona , Spain
| | - Andres Felipe Cardona
- Thoracic Oncology Unit, Clinical and Translational Oncology Group, Clinica del Country , Bogotá , Colombia
| | - Miguel Angel Molina
- Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus University Institute , Barcelona , Spain
| | - Rafael Rosell
- Pangaea Oncology, Laboratory of Molecular Biology, Quiron-Dexeus University Institute , Barcelona , Spain.,Cancer Biology and Precision Medicine, Institut d'Investigació en Ciències Germans Trias i Pujol , Badalona , Spain.,Institute of Oncology Rosell (IOR), Quiron-Dexeus University Institute , Barcelona , Spain.,Institut Català d'Oncologia, Hospital Germans Trias i Pujol , Badalona , Spain
| |
Collapse
|